Cargando…

P63 and P73 Activation in Cancers with p53 Mutation

The members of the p53 family comprise p53, p63, and p73, and full-length isoforms of the p53 family have a tumor suppressor function. However, p53, but not p63 or p73, has a high mutation rate in cancers causing it to lose its tumor suppressor function. The top and second-most prevalent p53 mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Bi-He, Hsu, Yun-Chien, Yeh, Fang-Yu, Lin, Yu-Rou, Lu, Rui-Yu, Yu, Si-Jie, Shaw, Jei-Fu, Wu, Ming-Han, Tsai, Yi-Zhen, Lin, Ying-Chen, Bai, Zhi-Yu, Shih, Yu-Chen, Hsu, Yi-Chiang, Liao, Ruo-Yu, Kuo, Wei-Hsin, Hsu, Chao-Tien, Lien, Ching-Feng, Chen, Chia-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313412/
https://www.ncbi.nlm.nih.gov/pubmed/35884795
http://dx.doi.org/10.3390/biomedicines10071490
_version_ 1784754073682051072
author Cai, Bi-He
Hsu, Yun-Chien
Yeh, Fang-Yu
Lin, Yu-Rou
Lu, Rui-Yu
Yu, Si-Jie
Shaw, Jei-Fu
Wu, Ming-Han
Tsai, Yi-Zhen
Lin, Ying-Chen
Bai, Zhi-Yu
Shih, Yu-Chen
Hsu, Yi-Chiang
Liao, Ruo-Yu
Kuo, Wei-Hsin
Hsu, Chao-Tien
Lien, Ching-Feng
Chen, Chia-Chi
author_facet Cai, Bi-He
Hsu, Yun-Chien
Yeh, Fang-Yu
Lin, Yu-Rou
Lu, Rui-Yu
Yu, Si-Jie
Shaw, Jei-Fu
Wu, Ming-Han
Tsai, Yi-Zhen
Lin, Ying-Chen
Bai, Zhi-Yu
Shih, Yu-Chen
Hsu, Yi-Chiang
Liao, Ruo-Yu
Kuo, Wei-Hsin
Hsu, Chao-Tien
Lien, Ching-Feng
Chen, Chia-Chi
author_sort Cai, Bi-He
collection PubMed
description The members of the p53 family comprise p53, p63, and p73, and full-length isoforms of the p53 family have a tumor suppressor function. However, p53, but not p63 or p73, has a high mutation rate in cancers causing it to lose its tumor suppressor function. The top and second-most prevalent p53 mutations are missense and nonsense mutations, respectively. In this review, we discuss possible drug therapies for nonsense mutation and a missense mutation in p53. p63 and p73 activators may be able to replace mutant p53 and act as anti-cancer drugs. Herein, these p63 and p73 activators are summarized and how to improve these activator responses, particularly focusing on p53 gain-of-function mutants, is discussed.
format Online
Article
Text
id pubmed-9313412
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93134122022-07-26 P63 and P73 Activation in Cancers with p53 Mutation Cai, Bi-He Hsu, Yun-Chien Yeh, Fang-Yu Lin, Yu-Rou Lu, Rui-Yu Yu, Si-Jie Shaw, Jei-Fu Wu, Ming-Han Tsai, Yi-Zhen Lin, Ying-Chen Bai, Zhi-Yu Shih, Yu-Chen Hsu, Yi-Chiang Liao, Ruo-Yu Kuo, Wei-Hsin Hsu, Chao-Tien Lien, Ching-Feng Chen, Chia-Chi Biomedicines Review The members of the p53 family comprise p53, p63, and p73, and full-length isoforms of the p53 family have a tumor suppressor function. However, p53, but not p63 or p73, has a high mutation rate in cancers causing it to lose its tumor suppressor function. The top and second-most prevalent p53 mutations are missense and nonsense mutations, respectively. In this review, we discuss possible drug therapies for nonsense mutation and a missense mutation in p53. p63 and p73 activators may be able to replace mutant p53 and act as anti-cancer drugs. Herein, these p63 and p73 activators are summarized and how to improve these activator responses, particularly focusing on p53 gain-of-function mutants, is discussed. MDPI 2022-06-23 /pmc/articles/PMC9313412/ /pubmed/35884795 http://dx.doi.org/10.3390/biomedicines10071490 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cai, Bi-He
Hsu, Yun-Chien
Yeh, Fang-Yu
Lin, Yu-Rou
Lu, Rui-Yu
Yu, Si-Jie
Shaw, Jei-Fu
Wu, Ming-Han
Tsai, Yi-Zhen
Lin, Ying-Chen
Bai, Zhi-Yu
Shih, Yu-Chen
Hsu, Yi-Chiang
Liao, Ruo-Yu
Kuo, Wei-Hsin
Hsu, Chao-Tien
Lien, Ching-Feng
Chen, Chia-Chi
P63 and P73 Activation in Cancers with p53 Mutation
title P63 and P73 Activation in Cancers with p53 Mutation
title_full P63 and P73 Activation in Cancers with p53 Mutation
title_fullStr P63 and P73 Activation in Cancers with p53 Mutation
title_full_unstemmed P63 and P73 Activation in Cancers with p53 Mutation
title_short P63 and P73 Activation in Cancers with p53 Mutation
title_sort p63 and p73 activation in cancers with p53 mutation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313412/
https://www.ncbi.nlm.nih.gov/pubmed/35884795
http://dx.doi.org/10.3390/biomedicines10071490
work_keys_str_mv AT caibihe p63andp73activationincancerswithp53mutation
AT hsuyunchien p63andp73activationincancerswithp53mutation
AT yehfangyu p63andp73activationincancerswithp53mutation
AT linyurou p63andp73activationincancerswithp53mutation
AT luruiyu p63andp73activationincancerswithp53mutation
AT yusijie p63andp73activationincancerswithp53mutation
AT shawjeifu p63andp73activationincancerswithp53mutation
AT wuminghan p63andp73activationincancerswithp53mutation
AT tsaiyizhen p63andp73activationincancerswithp53mutation
AT linyingchen p63andp73activationincancerswithp53mutation
AT baizhiyu p63andp73activationincancerswithp53mutation
AT shihyuchen p63andp73activationincancerswithp53mutation
AT hsuyichiang p63andp73activationincancerswithp53mutation
AT liaoruoyu p63andp73activationincancerswithp53mutation
AT kuoweihsin p63andp73activationincancerswithp53mutation
AT hsuchaotien p63andp73activationincancerswithp53mutation
AT lienchingfeng p63andp73activationincancerswithp53mutation
AT chenchiachi p63andp73activationincancerswithp53mutation